News

“We are very pleased to announce this important regulatory milestone,” said Alan H. Auerbach, Chief Executive Officer and President of Puma. “Although the use of trastuzumab in the

Following FDA approval, Citron Pharma immediately commenced shipments of the generic version of CRESTOR to its customers in the U.S. Ashok Mayya, Chief Operating Officer, noted, “Our team was

The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect and HydraSpace, generate ADCs with significantly improved therapeutic index

The ongoing studies were designed to explore the efficacy and safety of Odefsey among virologically suppressed adult patients switching from the tenofovir disoproxil fumarate (TDF)-based regimens Complera (emtricitabine 200mg/rilpivirine

New investors such as Staidson Hongkong Investment, international industrial investors and family offices as well as existing investors participated in the financing round. IFX-1 is a monoclonal anti-complement

The phase 3 study evaluated the effectiveness and safety of ABP 980 compared with trastuzumab in adult female patients with HER2-positive early breast cancer. There were 725 patients

The additional data and analyses constitute a major amendment to the BLA, resulting in an extension of the Prescription Drug User Fee Act (PDUFA) goal date by three

Maud Brandely, Chief Medical Officer of Transgene, said: “We are pleased to be continuing the development of our internally discovered and developed immunotherapy TG1050. The Phase 1/1b trial

Upon completion and once fully evaluated, which is expected to take approximately 9-12 months, this clinical trial material will also be available to recommence dosing of patients in the Company’s